Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether (a) his Department and (b) the Medicines and Healthcare products Regulatory Agency has received data from Astra Zeneca on the potential serious adverse effects of its covid-19 vaccine for a small number of recipients.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Department has not directly received data from AstraZeneca regarding potential adverse effects of their COVID-19 vaccine Vaxzevria, as it is not the appropriate body to receive this information. It instead relies on the expert advice of the Medicines and Healthcare products Regulatory Agency (MHRA).
All vaccine manufacturers have a legal responsibility to mitigate risk and monitor the safety and performance of vaccines throughout the product lifecycle. This includes a legal responsibility to transmit reports of suspected adverse reactions received directly to the MHRA. Following the MHRA’s receipt of the first Yellow Card reports of suspected thrombosis and associated thrombocytopaenia associated with the Vaxzevria vaccine in February 2021, AstraZeneca provided the Commission on Human Medicines’ Vaccine Benefit Risk Expert Working Group an analysis of the age stratified risk of thrombosis with thrombocytopenia associated with the AstraZeneca vaccine. This was assessed by the Commission on Human Medicines, with the Patient Information updated to state the risks of these events.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when the NHS England South West Complaints Team plans to provide a substantive response to the complaint made by the hon. member for Christchurch on behalf of a constituent under reference 2312-2050136; for what reason there has been no response to the complaint from the South West dental commissioning team; and what the contact details are for the person in charge of that team.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
I thank the hon. Member for Christchurch for bringing this matter to my attention. NHS England has advised that the trust has received the hon. Member's correspondence, and will respond in due course. In July 2023, the responsibility for primary care complaints, including dentistry, moved to local integrated care boards.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many complaints have been received by the NHS England South West Complaints Team in each of the last six months; how many emanated from the Dorset Integrated Care Board; and how many of those have been outstanding for more than two months.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The South West Complaints Team transferred from NHS England to the NHS Somerset Integrated Care Board (ICB), who now host the NHS South West Collaborative Commissioning Hub, on 1 July 2023. This followed the delegation of pharmacy, optometry, and dentistry associated complaints on 1 April 2023. The following table shows the number of complaints the South West Complaints Team received, and the proportion that were investigated for NHS Dorset ICB, each month from October 2023 to March 2024:
Month | Total received | Number from NHS Dorset ICB |
October 2023 | 181 | 25 |
November 2023 | 196 | 31 |
December 2023 | 119 | 21 |
January 2024 | 208 | 29 |
February 2024 | 191 | 44 |
March 2024 | 156 | 32 |
Total | 1,051 | 182 |
Of the 1,051 total complaints, 86 have been outstanding for more than two months. Of the 182 complaints from NHS Dorset ICB, 14 have been outstanding for more than two months.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the oral contribution by the Parliamentary Under Secretary of State at the Department of Health and Social Care during the debate on Covid-19: Response and Excess Deaths on Thursday 18 April 2024, Official Report, column 537, whether she has had recent discussions with (a) NICE and (b) the MHRA on their progress on reaching a decision on whether to recommend the use of Evusheld 2 to prevent covid-19.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department meets with the National Institute of Health and Care Excellence (NICE) regularly to discuss a range of issues, including access to medicines. The NICE has formally started its appraisal of AZD-3152, also known as sipavibart and referred to as Evusheld 2, ahead of the Medicines and Healthcare products Regulatory Agency’s (MHRA) decision on whether it should be given a United Kingdom marketing authorisation, and expects to invite stakeholder submissions in April 2024. Timelines for both the NICE’s guidance and licensing depend on data from the SUPERNOVA trial being available. AstraZeneca intends to submit clinical data to the NICE and the MHRA at the same time, with the aim that both organisations are able to reach decisions as close together as possible. If AZD-3152 is recommended as clinically and cost effective by the NICE, the National Health Service in England will be under a statutory requirement to fund AZD-3152 for eligible patients, in line with the NICE’s recommendations.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much the administration of the Vaccine Damage Payment Scheme cost the NHS Business Services Authority in (a) 2021, (b) 2022 and (c) 2023.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The NHS Business Services Authority (NHSBSA) administers the Vaccine Damage Payment Scheme, on behalf of the Department. Administration costs for the scheme were £600,000, £8.8 million, and £16.1 million for April 2021 to March 2022, April 2022 to March 2023, and April 2023 to March 2024, respectively. Payments made by the NHSBSA for the provision of medical records totalled £1,200, £72,000, and £73,100, for the same periods. The figures are provided to the nearest decimal place.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the cost to NHS England has been of reimbursing GP practices for providing services to (a) non-UK and (b) non-registered UK citizens in each of the last three years for which information is available.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
General practices (GPs) are paid for providing essential services to all their patients via global sum payments, which are weighted to take patient needs into account. Therefore, there are no dedicated GP payments for providing services to non-United Kingdom or non-registered UK citizens, and the Department does not hold data on GP patient lists by nationality.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what evidence of (a) identity and (b) immigration status GPs require from patients seeking to access their services; and whether her Department provides guidance to GPs on ensuring that identification provided by those people is genuine.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Patients have the legal right to choose a general practice (GP) that best suits their needs. An individual should not be refused registration or appointments because they do not have proof of address or personal identification. Patients do not need to provide proof of address or immigration status, identification, or a National Health Service number to register with a GP. The vast majority of migrants are required to pay the Immigration Health Surcharge when applying for a visa to stay in the United Kingdom for longer than six months.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential impact of the extra allocations of money made from the discharge fund to the (a) NHS and (b) local authorities in Dorset in the 2023-24 financial year on the (i) timeliness and (ii) effectiveness of the discharge of patients from NHS hospitals.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
The Government is investing an additional £600 million for 2023/24 and £1 billion for 2024/25, through the Discharge Fund, to support the National Health Service and local authorities in ensuring timely and effective discharge from hospital. As part of their allocations for 2023/24, NHS Dorset Integrated Care Board received £5.7 million, Bournemouth, Christchurch and Poole Council received £1.9 million, and Dorset Council received £1.7 million. There will be an independent evaluation of the Discharge Fund for 2023/24 and 2024/25.
Nationally, this funding has supported more people to be discharged more quickly with more appropriate support. The number of people discharged from hospital with packages of health and social care support increased by 10% between the end of February 2023 and the end of February 2024. Thanks to this improved patient flow hospitals have been able to admit and treat more patients during this period.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will publish the Regulatory Policy Committee's original opinion on the Tobacco and Vapes Bill submitted to her Department on 12 February 2024; if she will outline the changes she has made to that Bill since receiving that opinion; and what discussions she has had with the Regulatory Policy Committee on the expected timetable for their submission of the revised opinion.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Smoking is responsible for approximately 80,000 deaths a year in the United Kingdom, and causes around one in four cancer deaths in the UK. It also costs our country £17 billion a year, and puts a huge burden on the National Health Service. That is why we have introduced the Tobacco and Vapes Bill to create the first smokefree generation, and enable us to further crack down on youth vaping. The Tobacco and Vapes Bill is available at the following link:
https://bills.parliament.uk/bills/3703
On 12 February 2024 the Regulatory Policy Committee (RPC) gave opinion on the Tobacco and Vapes Bill impact assessment and rated it green (fit for purpose). However, on 19 March 2024, ahead of the introduction of the bill, a revised version was sent to the RPC for comment. This included changes to reflect the inclusion of Northern Ireland in the bill, following the formation of a Northern Ireland Executive, and a power in the bill to enable the current notification system for nicotine vapes to also cover non-nicotine vapes and other consumer nicotine products, for instance nicotine pouches. The RPC have publicly stated that they welcome the resubmission of the revised impact assessment, and we expect a revised opinion to be issued shortly. The statement from the RPC is available at the following link:
https://www.gov.uk/government/news/the-tobacco-and-vapes-bill-statement-from-the-rpc
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that the Regulatory Policy Committee's revised opinion on the Tobacco and Vapes Bill is published by 16 April 2024.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Smoking is responsible for approximately 80,000 deaths a year in the United Kingdom, and causes around one in four cancer deaths in the UK. It also costs our country £17 billion a year, and puts a huge burden on the National Health Service. That is why we have introduced the Tobacco and Vapes Bill to create the first smokefree generation, and enable us to further crack down on youth vaping. The Tobacco and Vapes Bill is available at the following link:
https://bills.parliament.uk/bills/3703
On 12 February 2024 the Regulatory Policy Committee (RPC) gave opinion on the Tobacco and Vapes Bill impact assessment and rated it green (fit for purpose). However, on 19 March 2024, ahead of the introduction of the bill, a revised version was sent to the RPC for comment. This included changes to reflect the inclusion of Northern Ireland in the bill, following the formation of a Northern Ireland Executive, and a power in the bill to enable the current notification system for nicotine vapes to also cover non-nicotine vapes and other consumer nicotine products, for instance nicotine pouches. The RPC have publicly stated that they welcome the resubmission of the revised impact assessment, and we expect a revised opinion to be issued shortly. The statement from the RPC is available at the following link:
https://www.gov.uk/government/news/the-tobacco-and-vapes-bill-statement-from-the-rpc